NightstaRx Expands Leadership Team, Names Gregory Robinson, Ph.D., as Chief Scientific Officer

LONDON--(BUSINESS WIRE)--NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, today announced that Gregory Robinson, Ph.D., has joined Nightstar as Chief Scientific Officer. He will lead Nightstar’s research programs advancing novel gene therapy candidates to address compelling unmet needs in patients at risk of vision loss and blindness. In his new role, Dr. Robinson will report directly to Nightstar’s CEO David